The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 05, 2021

Filed:

Jul. 19, 2019
Applicant:

Sichuan Kelun-biotech Biopharmaceutical Co., Ltd., Sichuan, CN;

Inventors:

Baiyong Li, Guangdong, CN;

Tongtong Xue, Sichuan, CN;

Yu Xia, Guangdong, CN;

Zhongmin Maxwell Wang, Guangdong, CN;

Liang Xiao, Sichuan, CN;

Lichun Wang, Sichuan, CN;

Jingyi Wang, Sichuan, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/46 (2006.01); C07K 14/705 (2006.01); C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01); A61P 35/02 (2006.01);
U.S. Cl.
CPC ...
C07K 16/468 (2013.01); A61K 39/395 (2013.01); A61K 47/6803 (2017.08); A61P 35/02 (2018.01); C07K 14/70532 (2013.01); C07K 16/2827 (2013.01); C07K 16/2896 (2013.01); C07K 16/462 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01); C07K 2319/50 (2013.01);
Abstract

The present invention belongs to the field of tumor therapy and molecular immunology, and relates to a PDL-1 antibody, a pharmaceutical composition thereof and use thereof. In particular, the present invention relates to a PDL-1 monoclonal antibody or an antigen-binding fragment thereof, wherein the monoclonal antibody has a heavy chain variable region comprising CDRs as set forth in SEQ ID NOs: 15-17; and/or has a light chain variable region comprising CDRs as set forth in SEQ ID NOs: 18-20. The monoclonal antibody of the present invention can bind to PDL-1 specifically, and specifically remove immunosuppressive function of PDL-1 and activate T lymphocytes.


Find Patent Forward Citations

Loading…